BoChuang BioTech completes Pre-A+ round financing to empower new medical development with collagen controlled assembly technology

Recently, BoChuang BioTech announced the completion of a tens of millions RMB Pre-A+ round financing, with this round receiving exclusive strategic investment from Sunland Fund, a professional investment institution in the healthcare sector. This marks the fourth round of financing for BoChuang BioTech within three years. The continued investment and deep recognition from the capital market not only confirm BoChuang BioTech's strong research and development capabilities and promising commercialization potential but also inject new momentum into the high-quality development of China's high-end medical device industry.

BoChuang BioTech specializes in the field of innovative implantable biomedical materials, building its corporate moat with original core technologies. Its core competitiveness stems from the high-purity collagen production and controllable electrochemical assembly processing technology (EDP) developed by a team led by Professor Liu Changsheng, an academician of the Chinese Academy of Sciences, and Professor Qu Xue, recipient of the National Science Fund for Distinguished Young Scholars. This innovative technology, with independent intellectual property rights, achieves precise control over the directional arrangement of molecules such as high-purity collagen through electric fields, laying the underlying technological foundation for the functional and innovative design of high-end implantable medical devices. It serves as the core support for BoChuang BioTech's research and development layout in multiple fields of high-end implantable devices, while also building a technically difficult-to-replicate barrier within the industry.

Relying on its original EDP technology platform, BoChuang BioTech has achieved multiple technological breakthroughs and key advancements in product implementation in core areas of high-end implantable devices, including ophthalmology, stomatology, and skin repair. It continues to launch products with high clinical value and technological innovation. The collagen artificial corneal stromal sheet (E-Col) independently developed by BoChuang BioTech has been officially initiated clinical enrollment research at the Eye & ENT Hospital of Fudan University. This product, precisely optimized at the molecular level, has a light transmittance exceeding 95%, with tensile strength and elastic modulus perfectly meeting clinical implantation standards. It can effectively reduce the risk of immune rejection and vascular invasion, providing a high-quality solution for the localization of high-end ophthalmic implantable devices in China. The guided oral bone tissue membrane has completed key technology verification and has entered the countdown phase for clinical application submission, representing an important innovative achievement in the field of high-end stomatology implantable materials.

BoChuang BioTech's next round of financing is about to commence, with FengHe Capital continuing to serve as the exclusive financial advisor for subsequent financing.